# Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

> **NCT00349518** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Chronic Myeloid Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00349518
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-12
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00349518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00349518, "Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00349518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*